Roche's Giredestrant Combination Significantly Improved Progression-free Survival in ER-positive Advanced Breast Cancer in Phase III EvERA Data Published in New England Journal of Medicine
October 02, 2026
October 02, 2026
BASEL, Switzerland, Oct. 2 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
Roche's giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
* Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus stan . . .
* * *
Roche's giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine
* Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus stan . . .